Serena Williams Migraine Ad Is Misleading: FDA
Date
9/12/2024 12:15:48 AM
(MENAFN- The Peninsula)
Bloomberg
AbbVie Inc.'s TV advertisements featuring tennis legend Serena Williams make misleading claims about the effectiveness of its migraine headache medication, according to US regulators.
AbbVie's TV spots say that all patients who take the drug, called Ubrelvy, can expect their migraine pain to be eliminated after a single dose, and that one dose works fast against migraines. None of these claims have been demonstrated in clinical trials, the FDA said in a warning letter dated August 29.
"These violations are concerning from a public health perspective,” the FDA wrote, adding that "the use of a celebrity athlete in this TV ad amplifies the misleading representations and suggestions made and increases the potential for audiences to find the misleading promotional communication more believable due to the perceived credibility of the source.”
AbbVie is required to respond to the letter within 15 working days with a plan to either discontinue the ads and any promotional materials with these claims, or to cease distribution of Ubrelvy. The company also has the option argue that its product isn't in violation of federal advertising regulations.
"We are actively addressing the FDA enforcement action regarding the TV commercial referenced in the letter, which stopped airing in the first half of this year,” a spokesperson for AbbVie said in an emailed statement, adding the company "will continue to further correspond with the FDA on this matter.”
Read Also
Amazon to invest £8 bn in UK in boost for new Labour govt
France foiled 3 attack plots targeting Paris Olympics, prosecutor says
Chelsea midfielder Enzo Fernandez gets 6-month driving ban
MENAFN12092024000063011010ID1108664881
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.